Comment on “Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)”

Diabetes, Obesity and Metabolism

Volumn 21, Issue 2, 2019, Pages 444-445

  Ryan, Patrick B ^a   Rosenthal, Norm ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; DATA BASE; DIABETIC PATIENT; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HOSPITALIZATION; HUMAN; LETTER; LIMB AMPUTATION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; AMPUTATION;

AMPUTATION; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85059827885     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13509     Document Type: Letter

References (2)

1. Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D) [published online ahead of print 25 June, 2018]. Diabetes Obes Metab. https://doi.org/10.1111/dom.13424.
2. Ryan P, Buse JB, Schuemie M, et al. Canagliflozin (CANA) versus other antihyperglycemic agents on the risk of below-knee amputation (BKA) for patients with T2DM: a real world analysis of >700,000 US patients. Poster presented at: 78th Scientific Sessions of the American Diabetes Association; June 22-26, 2018; Orlando, FL.